Wanbury's Patalganga Facility Achieves Zero Observation Korea FDA Inspection Success
Wanbury Limited achieved a significant regulatory milestone as its Patalganga manufacturing facility completed the Korea FDA (MFDS) inspection with zero observations, confirming cGMP compliance per international rules. The three-day inspection conducted by two inspectors from 7th-9th April adds to the company's track record of regulatory excellence across multiple facilities and international authorities including USFDA and Brazil's Anvisa.
*this image is generated using AI for illustrative purposes only.
Wanbury Limited has successfully completed the Korea FDA (Ministry of Food and Drug Safety - MFDS) regulatory inspection at its Patalganga manufacturing facility with zero observations, confirming cGMP compliance per international rules. The inspection was conducted from 7th April to 9th April by two inspectors over three days.
Inspection Details and Outcome
The Korea FDA inspection at the Patalganga site concluded without any regulatory issues, marking a significant achievement for the pharmaceutical company's quality assurance and regulatory compliance efforts. The zero observation outcome confirms the facility's adherence to current Good Manufacturing Practices (cGMP) as per international standards.
| Parameter | Details |
|---|---|
| Inspection Authority | MFDS (Korea FDA) |
| Facility Location | Patalganga |
| Inspection Duration | 3 days (7th-9th April) |
| Number of Inspectors | 2 |
| Inspection Outcome | Zero Observations |
| Compliance Status | cGMP per International Rules |
PIC Membership and Global Recognition
The Ministry of Food and Drug Safety (MFDS) is part of the Pharmaceutical Inspection Co-operation Scheme (PIC), which enhances the international recognition of this regulatory approval. This membership strengthens the global acceptance of the inspection standards and outcomes.
Multi-Site Regulatory Excellence
Wanbury's regulatory success extends across multiple facilities and international authorities. Both API manufacturing sites at Patalganga and Tanuku are USFDA approved and continue to maintain cGMP compliance. The company has achieved a consistent track record of zero observations across different regulatory bodies.
| Facility | Regulatory Authority | Outcome |
|---|---|---|
| Patalganga | USFDA | Zero Observation (Earlier) |
| Tanuku | Anvisa (Brazil FDA) | Zero Observation |
| Patalganga | Korea FDA (MFDS) | Zero Observation (Latest) |
Infrastructure Development
The company is strengthening its infrastructure by adding a new state-of-the-art manufacturing block at its Andhra Pradesh site for new APIs, which is currently under validation and commercialisation. This expansion demonstrates Wanbury's commitment to enhancing its manufacturing capabilities and capacity.
Historical Stock Returns for Wanbury
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.43% | -5.71% | +12.09% | -1.21% | +4.03% | +135.44% |
Will Wanbury leverage this Korea FDA approval to expand its market presence in South Korea and other Asian markets?
How will the new state-of-the-art manufacturing block at the Andhra Pradesh site impact Wanbury's production capacity and revenue growth?
Could this regulatory success attract new international partnerships or licensing deals for Wanbury's API products?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
